5,907 Views
By: Metacafe Affiliate U
225,197 Views
By metaops
19,455 Views
By: Metacafe Affiliate U
Final Day Highlights - 2012 Coca-Cola Quiksilve...
10,087 Views
By: Metacafe Affiliate U
Think Bikes - Street Ride with Joel Bennett , S... [HD]
129,817 Views
312,379 Views
500,590 Views
By dibin007
423,467 Views
By vishal91093
750,521 Views
By simplevivi
220,689 Views
By mustang75
588,480 Views
By VITMAN51
Str 10 Rollover During Burnout!
260,106 Views
By onebradh
102,273 Views
By Pro_Muff_Diver
754,391 Views
By xuda
Con Estos Amigos Pa Ke Kiero Enemigos
431,451 Views
By the.memin
136,738 Views
By ambiz
1,173,003 Views
By MohamedSalah25
Cat Showing Disappointment After Missing Her Hu...
934,894 Views
By dapip
1,044,572 Views
By demaxio
Britney Spears - Circus (Official Music Video)
790,997 Views
By Music
101,503 Views
By wiTTy1991
Bruce Lee - Catch His Speed If U Can
672,701 Views
1,815,064 Views
By BAD-BOYS
Fold a Piece of Clothing in Just 2 Seconds Simple.
695,432 Views
By diego0042
1,288,527 Views
By BAD-BOYS
00:31
246,805 Views
By djsoheil
02:51
The Painful Moments of Football
476,291 Views
By olegator911
00:22
692,715 Views
01:08
869,748 Views
By Henry_14
00:47
THE Best Ever Goal: Roberto Carlos, Incredible...
1,250,733 Views
By newac
00:39
1,350,417 Views
By Bad Seed
01:18
414,668 Views
By el_zar_tk
00:31
383,050 Views
By olligarh
00:23
386,148 Views
By B4D B0YZ 420
00:56
368,870 Views
By Amp47515
Add video views to your Facebook Timeline:
CRWENewswire, Stocks to Watch. Threshold Pharmaceuticals Inc - THLD - reported that a global agreement was signed with Merck KGaA, Darmstadt, Germany, to co-develop and commercialize TH-302, Threshold’s small molecule hypoxia-targeted drug. Threshold will receive an upfront payment of $25 million and could receive up to $35 million in additional development milestones during 2012. Threshold is also eligible to receive a $20 million milestone payment based on positive results from its randomized Phase 2 trial in pancreatic cancer. Total potential milestone payments are $525 million, comprised of $280 million in regulatory and development milestones and $245 million in sales-based milestones.
***********************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.